June 05, 2023
3 min watch
Save
VIDEO: Phase 3 data promising for iDose TR
You've successfully added to your alerts. You will receive an email when new content is published.
Click Here to Manage Email Alerts
Click Here to Manage Email Alerts
We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.
Key takeaways:
- There were no significant issues with endothelial cell loss.
- No adverse events have been seen in exchange studies with the iDose TR.
SAN DIEGO — In this Healio Video Perspective from the ASCRS meeting, I. Paul Singh, MD, discusses phase 3 data on the iDose TR implant from Glaukos.
“Not only did we get 8.5 mm Hg reduction in IOP, we actually found out it was superior to that of topical [prostaglandin analog],” he said.
Published by:
Sources/Disclosures
Collapse
Source:
Healio Interviews
Disclosures:
Singh reports speaking and consulting for Glaukos.
Read more about
You've successfully added to your alerts. You will receive an email when new content is published.
Click Here to Manage Email Alerts
Click Here to Manage Email Alerts
We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.